Literature DB >> 2857803

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial.

H Hess, A Mietaschk, G Deichsel.   

Abstract

240 patients were admitted to a double-blind study to determine the effect of long-term treatment with platelet-function inhibiting agents on occlusive arterial disease in the lower extremities. Patients were randomised into 1 of 3 treatment groups: aspirin 330 mg; dipyridamole 75 mg and aspirin 330 mg; or matching placebo 3 times daily. The duration of treatment was 2 years. Arteriography was carried out at the beginning of the study and 2 years later or before if deterioration was observed. 199 patients completed the study according to the trial protocol. The serial arteriograms were assessed in pairs qualitatively, by means of simple comparative viewing, and semiquantitatively with Bollinger's score system. Progression of the disease was most pronounced in the placebo-treated group, less so in the aspirin-treated group, and least of all in the dipyridamole-and-aspirin group. Patients who smoke and those with hypertension may benefit most from treatment with the 2 preparations under investigation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857803     DOI: 10.1016/s0140-6736(85)91144-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

Review 1.  Current strategies in the diagnosis and management of lower extremity peripheral vascular disease.

Authors:  T J Wilt
Journal:  J Gen Intern Med       Date:  1992 Jan-Feb       Impact factor: 5.128

2.  Dialysis: vascular access: not enough light at the end of the tunnel?

Authors:  Raymond Vanholder; Francis Verbeke; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

Review 3.  North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.

Authors:  M Eccles; N Freemantle; J Mason
Journal:  BMJ       Date:  1998-04-25

4.  Prophylactic antiplatelet therapy in peripheral arterial disease.

Authors:  R Verhaeghe
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.

Authors:  M Verstraete
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6. 

Authors:  C Diehm; H Heidrich; F Spengel; K L Schulte; W Theiss
Journal:  Internist (Berl)       Date:  2000-11       Impact factor: 0.743

7.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08

Review 8.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

9.  Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review.

Authors:  Christos Kasapis; Hitinder S Gurm
Journal:  Curr Cardiol Rev       Date:  2009-11

10.  Stenosis and vascular damage as a cause of thrombosis in the dog femoral artery.

Authors:  M Prosdocimi; A Zatta; M Finesso
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.